key: cord-0836294-cqrvw0bn authors: Fennelly, Mehael; Keane, Joseph; Dolan, Lorraine; Plant, Barry J.; O'Connor, David; Sodeau, John; Prentice, Michael B. title: Containment of Procedure-Associated Aerosols by an Extractor Tent: effect on nebulised drug particle dispersal date: 2021-01-20 journal: J Hosp Infect DOI: 10.1016/j.jhin.2021.01.009 sha: 9417dfdc4b52ef3df2053e201ae2f5bb609ff548 doc_id: 836294 cord_uid: cqrvw0bn BACKGROUND: Several medical procedures involving the respiratory tract are considered ‘aerosol generating’. Aerosols from these procedures may be inhaled by bystanders and there are consequent concerns regarding infection transmission, or, specific to nebulised therapy, secondary drug exposure. AIMS: Assess the efficacy of a proprietary HEPA-filtering extractor tent on reducing the aerosol dispersal of nebulised bronchodilator drugs. METHODS: The study was conducted in an unoccupied outpatient room at St. James’s Hospital, Dublin. A novel real-time, fluorescent particle counter, the Wideband Integrated Bioaerosol Sensor (WIBS), monitored room air continuously for three hours. Baseline airborne particle counts and counts during nebulisation of bronchodilator drug solutions were recorded. FINDINGS: Nebulising within the tent prevented any increase over background levels, nebulising directly into room air resulted in mean fluorescent particle counts of 4.75 x 10(5)/m(3) and 4.21 x 10(5)/m(3) for Ventolin and Ipramol, respectively, representing more than 400-fold increases over the mean background count. >99.3% of drug particles were less than 2 μm in diameter, small enough to enter the lower respiratory tract. CONCLUSION: These results show the extractor tent was completely effective in preventing airborne spread of drug particles of respirable size from nebulised therapy. This suggests extractor tents of this kind would be efficacious in preventing airborne infection from aerosol-generating procedures during the COVID-19 pandemic. Infectious aerosols are airborne particles containing pathogens. Infectious aerosols from 51 coughing, sneezing, and talking can transmit disease from person-to-person by deposition in 52 the respiratory tract. While numerous particle sizes are generated by these activities, those 53 <10 µm in diameter (conventionally called aerosols) remain suspended in air for long periods 54 of time increasing the risk of inhalation by those more than 1 m away, and particles <5 µm , and tuberculosis (TB) [3, 4] . Preliminary data indicates 60 that SARS-CoV-2 could be spread in this manner [5] , including the demonstration that 61 airborne particles less than 5 µm in diameter carry the highest coronavirus RNA titres [5] . 62 63 Several medical procedures involving the respiratory tract, including intubation, non-invasive 64 ventilation and nebuliser therapy, are known to be 'aerosol generating ' [6] . These aerosol 65 generating procedures create aerosols in addition to those from breathing and speaking. 66 Aerosols from these procedures may be exhaled from patients being treated and inhaled by 67 bystanders. Thus far the only airway treatment delivery procedure for which there is clear 68 evidence for aerosol production is endotracheal intubation [7] . Bronchoscopy and sputum 69 induction have long been associated with nosocomial transmission of TB [8, 9] . More 70 recently bronchoscopy, and respiratory and airway suctioning resulted in above baseline 71 (background) values for the detection of H1N1 influenza aerosols [10] . 72 73 J o u r n a l P r e -p r o o f Deliberate aerosolization by a nebuliser is a common method of drug delivery to the 74 respiratory tract [11] . A nebuliser is a device that converts liquid into polydisperse aerosol 75 droplets suitable for inhalation [11] . In the commonest type, a jet nebuliser, the liquid drug 76 solution is broken up into polydisperse droplets by compressed air or oxygen and the larger 77 droplets are then removed by baffles, where they amalgamate and fall back into the reservoir 78 to be recirculated. Most of the drug released from nebulisers is in particles of 1-5 µm 79 diameter, as required for therapeutic efficiency. Studies with radiolabelled inhaled 80 aerosolised drug particles show that that during inhalation only 44% of inhaled aerosols with 81 mass median diameter of 10.3 µm reach the lungs, while 79% of aerosols with mass median 82 diameter (MMD) of 1.8 µm are deposited in the lungs [12] . Up to two thirds of the prescribed 83 dose is released from the nebuliser or exhaled, passing into the surrounding air [13, 14] . 84 85 There has been some concern about nebulised drug therapy and transmission of SARS-Co-V-86 transmission [27] . The two main types of controls used to prevent airborne drug or infectious 106 particle dispersion are local exhaust ventilation (LEV) devices and negative pressure isolation 107 rooms. LEV devices are in principle the most efficient control method, capturing infectious 108 particles close to the point of generation. The preferred type of LEV is a complete enclosure 109 (booth or tent) surrounding the patient with exhaust air passage via a high-efficiency 110 particulate air (HEPA)-filter [28, 29] . Tents have flexible walls with rigid frames and require 111 minor assembly and disassembly [29] . 112 Although LEV devices of this type are in widespread use, efficacy at reducing dispersal has 113 been assessed by chemical quantitation [23] rather than direct aerosol particle detection. particle counts returned to background levels ( Figure . 3), within mean + 3*SD of pre-136 nebulisation numbers (Table 1) . 137 A PARI LC SPRINT jet nebuliser placed on a chair 40 cm above the ground ( Figure . The WIBS-4A records raw data as CSV files on a directly connected laptop (Fennelly et al, 165 submitted). A single CSV file records a maximum of 30,000 particles or up to a maximum 166 duration of 3 hours. During the 3-hour measurement period a total of 22 raw Excel files were 167 collected comprising of a total of 162,487 individual particles. The data were imported into 168 MATLAB (Math Works Inc., USA) and processed further into appropriate files, subsets, and 169 matrices. They were then summed into 10 second intervals and analysed and graphed using R 170 Studio 1.1.383. P-values were calculated with a t-test (parametric) or Mann-Whitney U test 171 (non-parametric). 172 The study observation timeline is shown in Figure 2 , starting at 11:42 and finishing at 14:11. 174 Background levels were measured for 21 minutes before nebulisation of drugs. WIBS was in 175 the same location for both in-tent and out-of-tent nebuliser analysis. Ipramol then Ventolin 176 was nebulised, twice inside the tent, and then once outside the tent. 177 There was no increase in fluorescent particle counts over background associated with 178 nebulising drugs inside the tent (Table I, Figure 2 ). Nebulising drugs directly into room air 179 resulted in a >700-fold increase in fluorescent particle counts over background for Ventolin 180 and Ipramol (Table I, Figure 2 ). 181 As for laboratory in vitro experiments with nebulised Ventolin and Ipramol (Fennelly et al, 182 submitted), 100% of particles counted following open nebulisation were fluorescent in all 183 channels, but highest intensity was in the FL1 channel. Less than 1% of background particles 184 were fluorescent. Mean particle size was 1.26 µm and 1.27 µm with size range of ±0.06 µm 185 and ±0.19 µm for Ventolin and Ipramol, respectively. Enclosing an operating nebuliser inside 186 the tent therefore prevents exposure to these small drug particles outside the tent (Table I) . 187 The mean fluorescent particle count in the room during operation of the tent was slightly (but 188 significantly) lower than the background with the tent filter pump off for both in-tent 189 nebulised drug time periods, (P<0.001) (Table I, Figure 2) . 190 191 192 There were two potential confounding events. Firstly, after a drug sample had run dry while 193 nebulising in the tent, the tent had to be breached (opened) in order to change the nebuliser 194 solutions. The time during drug solution change is referred to as "Change". During nebuliser 195 change-over a significant increase in fluorescent particle counts was observed compared to 196 the background (P<0.001) (Table I, Figure 2 ). However, it must be noted that although this 197 increase is significant it is quite small in terms of particle counts, on average increasing by 198 0.047/s, and the maximum counts observed differing by only one particle. Secondly, the entry 199 of a nurse to the room from 12:22-12:26 (Figure 2 ) was associated with a significant 2-fold 200 increase in mean fluorescent particles on a very low background from 12:23 minutes after 201 Ventolin nebulisation commenced, to Ventolin + 6.00 minutes. However, a significant 12.5-202 fold increase in non-fluorescent particles consistent with dust was observed. Airborne transmission and precautions: facts and myths Evidence of airborne 268 transmission of the severe acute respiratory syndrome virus Heifets LB Cough-271 generated aerosols of Mycobacterium tuberculosis: a new method to study 272 infectiousness 275 Variability of infectious aerosols produced during coughing by patients with 276 pulmonary tuberculosis Aerodynamic analysis of 279 SARS-CoV-2 in two Wuhan hospitals A review of the risks and disease 281 transmission associated with aerosol generating medical procedures Borchard G Non-invasive pulmonary 284 aerosol delivery in mice by the endotracheal route Ridzon R Potential 287 nosocomial exposure to Mycobacterium tuberculosis from a bronchoscope Foskin E Induced 290 sputum and bronchoscopy in the diagnosis of pulmonary tuberculosis 293 Influenza aerosols in UK hospitals during the H1N1 (2009) pandemic-the risk of 294 aerosol generation during medical procedures The science of nebulised drug delivery Effect of nebulised aerosol size on lung deposition in patients 298 with mild asthma Pilbeam SP Secondhand Aerosol Exposure during Mechanical 300 Ventilation with and without Expiratory Filters: An in-vitro study 303 Investigation of the quantity of exhaled aerosols released into the environment during 304 nebulisation Use of Aerosolised Medications at Home for COVID-19. The Lancet 306 Respiratory medicine 2020 Acute asthma management during SARS-CoV2-pandemic 2020 Aerosol-generating procedures and infective risk to 311 healthcare workers from SARS-CoV-2: the limits of the evidence Ventilation Techniques and Risk for Transmission of Coronavirus 315 Including COVID-19: A Living Systematic Review of Multiple Streams of 316 Evidence Aerosol generating 318 procedures and risk of transmission of acute respiratory infections to healthcare 319 workers: a systematic review Barjaktarevic IZ Nebulized Treatments and the Possible Risk of 321 Coronavirus Transmission: Where Is the Evidence? Chronic obstructive pulmonary 322 diseases Public Health England COVID-19: infection prevention and control guidance Occupational risk 326 factors and asthma among health care professionals. American journal of respiratory 327 and critical care medicine Postmus PE Assessing a system to 329 capture stray aerosol during inhalation of nebulized liposomal cisplatin Exposure of health care workers to aerosolized 332 pentamidine Krilov LR Safety issues related to the administration of ribavirin. The Pediatric 334 infectious disease journal 336 Personal protective equipment for health care workers who work with hazardous 337 drugs Induced sputum analysis: step by step. Breathe: Eur 339 Respiratory Soc Conducting sputum induction safely Effective TB Solutions California: Curry National Tuberculosis Center (CNTC) 1999: 342 9 Tuberculosis infection control: a practical manual for preventing 344 TB Time Fluorescence Instrumentation to Monitor Ambient Primary Biological Aerosol 347 Particles (PBAP) Respiratory virus shedding in exhaled breath and efficacy of face masks Design 352 and Evaluation of a Portable Negative Pressure Hood with HEPA Filtration to Protect 353 Health Care Workers Treating Patients with Transmissible Respiratory Infections The authors gratefully acknowledge the UCC Environmental Research Institute for 257 laboratory accommodation during School of Chemistry refurbishment. 258